Association of anaplastic lymphoma kinase variants and alterations with ensartinib response duration in non-small cell lung cancer

Autor:	Ning Wu, Zewei Zhang, Shijun Zhao, Xiaomin Zheng, Lv Lv, Lieming Ding, Qi Sun, Sicong Wang, Yu-Jing Jin, Xiuli Tao, Lina Zhou, Donghui Hou, Wei Song, Xiaoqing Liu
Rok vydání:	2021
Předmět:	Pulmonary and Respiratory Medicine Oncology Adult Male medicine.medical_specialty Lung Neoplasms Antineoplastic Agents Gene mutation ALK fusion Piperazines Metastasis Internal medicine hemic and lymphatic diseases Carcinoma Non-Small-Cell Lung medicine Anaplastic lymphoma kinase Humans Anaplastic Lymphoma Kinase Progression-free survival gene mutation Lung cancer ensartinib RC254-282 Retrospective Studies Univariate analysis Crizotinib business.industry Neoplasms. Tumors. Oncology. Including cancer and carcinogens progression‐free survival General Medicine Original Articles Middle Aged medicine.disease Progression-Free Survival Pyridazines Tumor progression radiomics Female Original Article business Tomography X-Ray Computed medicine.drug
Zdroj:	Thoracic Cancer Thoracic Cancer, Vol 12, Iss 17, Pp 2388-2399 (2021)
ISSN:	1759-7714
Popis:	Background Here, we aimed to assess the association of ALK variants and alterations with ensartinib response duration in NSCLC, and explore the potential value of computed tomography (CT) radiomic features in predicting progression‐free survival (PFS). Methods We enrolled 88 patients with identified ALK variant NSCLC in a multicenter phase 2 trial, and assessed the impact of ALK variants and secondary ALK alterations on the clinical outcome (response duration) of patients receiving ensartinib. We also established a multifactorial model of clinicopathological and quantitative CT radiomic features to predict PFS and risk stratification. Kaplan–Meier analysis was conducted to identify risk factors for tumor progression. Results Univariate analysis indicated a statistical difference (p = 0.035) in PFS among ALK variants in three classifications (V1, V3, and other variants). Secondary ALK alterations were adversely associated with PFS both in univariate (p = 0.008) and multivariate (p = 0.04) analyses and could identify patients at high risk for early progression in the Kaplan–Meier analysis (p = 0.002). Additionally, response duration to crizotinib The secondary ALK alterations were adversely associated with ensartinib response duration in NSCLC, and ALK variants might not correlate with PFS. CT quantitative radiomic signature could add prognostic prediction value of clinicopathological features.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf8c64c8dc730779dbbe68ab22c683b3 https://pubmed.ncbi.nlm.nih.gov/34288491 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.